Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 526 AL 540

Disease modifying treatments for Alzheimer's disease: Clinician perspectives

Pennington C, Apurva P, Chen A, Duncan A, Mackay G, Masters H, Paramore K, Russ T, Skinner H, Zeidler M.

J Alzheimers Dis. 2026 May;111(1):125-131. doi: 10.1177/13872877261429859. Epub 2026 Mar 25.

Nanomaterials for Alzheimer's disease: emerging strategies in diagnosis and therapy

Na Y, Bai J, Zhang N, Geng F, Wang X.

J Nanobiotechnology. 2026 Mar 21;24(1):398. doi: 10.1186/s12951-026-04281-w.

CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures

Abdel-Haleem AM, Casavant E, Toth B, Teng E, Monteiro C, Pandya NJ, Glock C, Hoogenraad CC, Friedman BA, Yeh FL, Anania VG, Novikova G.

Brain. 2026 Jan 8;149(1):150-162. doi: 10.1093/brain/awaf200.

Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy

Høilund-Carlsen PF, Alavi A, Costa T, Neve RL, Revheim ME, Barrio JR.

J Alzheimers Dis. 2026 Apr;110(3):1079-1084. doi: 10.1177/13872877261417548. Epub 2026 Mar 20.

Signalling Pathways Involved in Microglial Activation in Alzheimer's Disease and Potential Neuroprotective Role of Phytoconstituents

Ali MU, Anwar L, Ali MH, Iqubal MK, Iqubal A, Baboota S, Ali J.

CNS Neurol Disord Drug Targets. 2024;23(7):819-840. doi: 10.2174/1871527322666221223091529.

Effect of Natural Plant Products on Alzheimer's Disease

Varshney H, Siddique YH.

CNS Neurol Disord Drug Targets. 2024;23(2):246-261. doi: 10.2174/1871527322666230228102223.

Safety Analysis of Bapineuzumab in the Treatment of Mild to Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis

Gao Y, Guo J, Zhang F, Li Y.

Comb Chem High Throughput Screen. 2024;27(1):40-47. doi: 10.2174/1386207326666230419095813.

Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease

Rathod SS, Agrawal YO.

Curr Drug Res Rev. 2024;16(2):94-110. doi: 10.2174/2589977515666230502104021.

Emerging Nanotechnology for the Treatment of Alzheimer's Disease

Singh A, Ansari VA, Mahmood T, Ahsan F, Wasim R, Maheshwari S, Shariq M, Parveen S, Shamim A.

CNS Neurol Disord Drug Targets. 2024;23(6):687-696. doi: 10.2174/1871527322666230501232815.

Cholinergic Transporters Serve as Potential Targets in Alzheimer's Disease

Bist R, Bhatt DK.

Curr Mol Med. 2024;24(4):397-398. doi: 10.2174/1566524023666230505155302.

Is There a Role of Vitamin D in Alzheimer's Disease?

Plantone D, Pardini M, Caneva S, De Stefano N.

CNS Neurol Disord Drug Targets. 2024;23(5):545-553. doi: 10.2174/1871527322666230526164421.

Targeting Cellular Senescence: A Potential Therapeutic approach for Alzheimer's Disease

Singh S, Bhatt LK.

Curr Mol Pharmacol. 2024;17:e010623217543. doi: 10.2174/1874467217666230601113430.

New Insights into the Relationship between Nutrition and Neuroinflammation in Alzheimer's Disease: Preventive and Therapeutic Perspectives

De Marchi F, Vignaroli F, Mazzini L, Comi C, Tondo G.

CNS Neurol Disord Drug Targets. 2024;23(5):614-627. doi: 10.2174/1871527322666230608110201.

Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease

Chen J, Chen JS, Li S, Zhang F, Deng J, Zeng LH, Tan J.

Aging Dis. 2024 Feb 1;15(1):201-225. doi: 10.14336/AD.2023.0308.

Role of Alpha-7-Nicotinic Acetylcholine Receptor in Alzheimer's Disease

Singh S, Agrawal N, Goyal A.

CNS Neurol Disord Drug Targets. 2024;23(3):384-394. doi: 10.2174/1871527322666230627123426.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias